ACUTE MYELOID LEUKEMIA, REFRACTORY
Clinical trials for ACUTE MYELOID LEUKEMIA, REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOID LEUKEMIA, REFRACTORY trials appear
Sign up with your email to follow new studies for ACUTE MYELOID LEUKEMIA, REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental nanoparticle drug enters human testing for aggressive leukemia
Disease control Recruiting nowThis is an early-stage study to test the safety of a new drug called Ceramide NanoLiposome (CNL) in adults with acute myeloid leukemia (AML) that has returned or not responded to previous treatments. The main goal is to find a safe dose for future studies. Participants receive th…
Matched conditions: ACUTE MYELOID LEUKEMIA, REFRACTORY
Phase: PHASE1 • Sponsor: Keystone Nano, Inc • Aim: Disease control
Last updated Apr 01, 2026 22:56 UTC
-
Groundbreaking T-Cell therapy trial offers hope for kids with tough leukemia
Disease control Recruiting nowThis early-phase study is testing a new, genetically modified T-cell therapy called SC-DARIC33 in children and young adults (up to age 30) whose acute myeloid leukemia has returned or not responded to standard treatments. The main goals are to see if the therapy is safe to make a…
Matched conditions: ACUTE MYELOID LEUKEMIA, REFRACTORY
Phase: PHASE1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New hope for leukemia patients out of options
Disease control Recruiting nowThis study is testing a new drug called AB8939 for people with acute myeloid leukemia (AML) that has come back or hasn't responded to previous treatments. The main goals are to find a safe dose and see if the drug helps control the cancer. It's for patients who have already tried…
Matched conditions: ACUTE MYELOID LEUKEMIA, REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: AB Science • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
First human trial launches for experimental blood cancer drug
Disease control Recruiting nowThis early-stage study is testing a new drug called APL-4098 in adults with advanced forms of blood cancers like acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Researchers want to find the safest dose and see how well the drug works when given alone or combined …
Matched conditions: ACUTE MYELOID LEUKEMIA, REFRACTORY
Phase: PHASE1 • Sponsor: Apollo Therapeutics Ltd • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Scientists test supercharged immune cells in fight against tough leukemia
Disease control Recruiting nowThis early-stage study is testing a new treatment for adults with acute myeloid leukemia (AML) that has returned or not responded to other therapies. Researchers are combining specially trained immune cells, called NK cells, from a family donor with a drug called atezolizumab. Th…
Matched conditions: ACUTE MYELOID LEUKEMIA, REFRACTORY
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New CAR-T therapy targets Tough-to-Treat blood cancers
Disease control Recruiting nowThis early-stage trial is testing a new CAR-T cell therapy called ARD103 for patients with acute myeloid leukemia or myelodysplastic syndrome that has returned or hasn't responded to previous treatments. The study aims to find the safest and most effective dose while checking if …
Matched conditions: ACUTE MYELOID LEUKEMIA, REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: ARCE Therapeutics, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New immune cell therapy tested for Tough-to-Treat blood cancer
Disease control Recruiting nowThis is a first-in-human study to test the safety and find the right dose of a new type of CAR T-cell therapy for patients with acute myeloid leukemia (AML) that has come back or not responded to other treatments. The therapy involves modifying a patient's own immune cells to tar…
Matched conditions: ACUTE MYELOID LEUKEMIA, REFRACTORY
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
Hope for young leukemia patients: new 3-Drug combo trial launches
Disease control Recruiting nowThis study is testing whether adding a drug called venetoclax to two other medications (5-azacitidine and vorinostat) followed by standard chemotherapy can better control a severe blood cancer called acute myeloid leukemia (AML) in children and young adults. It is for patients wh…
Matched conditions: ACUTE MYELOID LEUKEMIA, REFRACTORY
Phase: PHASE1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Massive 4000-Patient study launches to map the fight against tough blood cancer
Knowledge-focused Recruiting nowThis study aims to collect real-world data on how patients with acute myeloid leukemia (AML) that has returned or is resistant to treatment fare across Europe. It will follow 4000 patients to understand survival rates, treatment responses, and which therapies are used in practice…
Matched conditions: ACUTE MYELOID LEUKEMIA, REFRACTORY
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:12 UTC